Shenzhen Lifotronic Technology Co (688389) - Total Assets
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) holds total assets worth CN¥2.53 Billion CNY (≈ $369.58 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Lifotronic Technology Co - Total Assets Trend (2016–2025)
This chart illustrates how Shenzhen Lifotronic Technology Co's total assets have evolved over time, based on quarterly financial data. Also see 688389 market cap for the company's overall valuation and market capitalisation.
Shenzhen Lifotronic Technology Co - Asset Composition Analysis
Current Asset Composition (December 2025)
Shenzhen Lifotronic Technology Co's total assets of CN¥2.53 Billion consist of 69.7% current assets and 30.3% non-current assets. Review Shenzhen Lifotronic Technology Co balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 56.0% |
| Accounts Receivable | CN¥173.64 Million | 6.2% |
| Inventory | CN¥183.04 Million | 6.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥99.72 Million | 3.6% |
| Goodwill | CN¥23.16 Million | 0.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Shenzhen Lifotronic Technology Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Shenzhen Lifotronic Technology Co for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Lifotronic Technology Co's current assets represent 69.7% of total assets in 2025, a decrease from 88.8% in 2016.
- Cash Position: Cash and equivalents constituted 56.0% of total assets in 2025, down from 82.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 6.5% of total assets.
Shenzhen Lifotronic Technology Co Competitors by Total Assets
Key competitors of Shenzhen Lifotronic Technology Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
USA | $1.81 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Eurobio Scientific SA
PA:ALERS
|
France | €259.11 Million |
|
Profound Medical Corp
TO:PRN
|
Canada | CA$62.28 Million |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
Shenzhen Lifotronic Technology Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.34 | 2.75 | 5.53 |
| Quick Ratio | 3.86 | 2.50 | 4.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.27 Billion | CN¥1.30 Billion | CN¥773.26 Million |
Shenzhen Lifotronic Technology Co - Advanced Valuation Insights
This section examines the relationship between Shenzhen Lifotronic Technology Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.28 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | CN¥2.81 Billion |
| Market Capitalization | $697.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Lifotronic Technology Co's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shenzhen Lifotronic Technology Co's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shenzhen Lifotronic Technology Co (2016–2025)
The table below shows the annual total assets of Shenzhen Lifotronic Technology Co from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.81 Billion ≈ $411.12 Million |
-2.94% |
| 2024-12-31 | CN¥2.89 Billion ≈ $423.56 Million |
+24.16% |
| 2023-12-31 | CN¥2.33 Billion ≈ $341.15 Million |
+28.06% |
| 2022-12-31 | CN¥1.82 Billion ≈ $266.40 Million |
+23.47% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.76 Million |
+14.34% |
| 2020-12-31 | CN¥1.29 Billion ≈ $188.70 Million |
+9.38% |
| 2019-12-31 | CN¥1.18 Billion ≈ $172.52 Million |
+45.21% |
| 2018-12-31 | CN¥811.93 Million ≈ $118.81 Million |
+14.29% |
| 2017-12-31 | CN¥710.40 Million ≈ $103.95 Million |
+42.79% |
| 2016-12-31 | CN¥497.52 Million ≈ $72.80 Million |
-- |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. researches, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. It offers a comprehensive range of in vitro diagnostic equipment and reagents, including electrochemiluminescence immunoassay analyzers, glycated hemoglobin analyzers, specific protein analyzers, blo… Read more